Skip to main content

This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

Adverse events reporting information can be found in the footer of this page.

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of the public. This website is not suitable for healthcare professionals outside of the United Kingdom.

I am a UK Healthcare Professional
No, I am a member of the public
 

Home
  • Register with Email
  • Sign In
  • RLT Home
  • Introduction to RLT
  • Neuroendocrine tumours
  • Prostate cancer

Popular Search

  • prrt
  • masterclass
  • part
  • 2022
  • 2023

Recent News

Pluvicto Clinical Trials
LUTATHERA® (lutetium [177Lu] oxodotreotide) Safety Information
Coming soon
Search
  1. Site map
Front page of RLT Hub
  • RLT Home
  • Neuroendocrine tumours
    • Introduction to GEP-NETs
      • Disease Background
      • Identifying Progression
      • Treatment Guidelines
    • Further Support
  • LUTATHERA® (lutetium [177Lu] oxodotreotide)
    • LUTATHERA
      • NETTER-1
      • NETTER-1 Overall Survival
      • Quality of Life with LUTATHERA®
      • LUTATHERA®: Power Against Progression
      • Early Intervention
      • Administration of LUTATHERA®
      • Patient Resources
      • Safety Information
  • PRRT Practical Resources
    • PRRT Practical Resources
      • Background to RLT
      • RCP/CPD approved GEP-NETs e-learning modules
      • PRRT Masterclass Videos 2021
      • PRRT Masterclass Videos 2020
        • Molecular Imaging in Neuroendocrine Tumours
      • Service Development Toolkit
        • Service Development Toolkit - Introduction
        • Service Development Toolkit - Exploring Potential Service Options
        • Service Development Toolkit - Implementation Resources
        • Service Development Toolkit - Starter Pack
        • Service Development Toolkit - Case Studies
      • BSG 2021 webinar
      • NCUK 2021 podcast
      • NETTER-1 OS webinar
      • RCNi Quality of Life webinar
      • Update from ECE 2021
  • Contact Us
  • Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan)
×

Ask Speakers

×

Medical Information Request

Welcome to the Radioligand Therapy Hub.

Please confirm whether you are a UK healthcare professional or a member of public.

Yes, I am a UK healthcare professional
No, I am a member of the public

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email [email protected] or call 01276 698370.

Privacy policy
Cookie Settings
Terms of use
Site directory

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.
Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ

UK | February 2025 | FA-11281060

This page is intended for UK healthcare professionals and other relevant decision makers only.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

©2025 Novartis Pharmaceuticals UK Limited. All rights reserved.